Only in Titles

Search results for: member

paperclip

#36472899   2022/12/06 To Up

How TikTok Is Being Used to Help Individuals Cope With Breast Cancer: Cross-sectional Content Analysis.

Acknowledging the popularity of TikTok, how quickly medical information can spread, and how users seek support on social media, there is a clear lack of research on breast cancer conversations on TikTok. There is a paucity of information on how these videos can advocate for those impacted by breast cancer as a means to provide support and information as well as raise awareness.
Corey H Basch, Grace C Hillyer, Bhavya Yalamanchili, Aldean Morris

2272 related Products with: How TikTok Is Being Used to Help Individuals Cope With Breast Cancer: Cross-sectional Content Analysis.

1 module1 module1 module1 module200 ug1 module

Related Pathways

paperclip

#36472896   2022/12/06 To Up

Digital Platform Uses for Help and Support Seeking of Parents With Children Affected by Disabilities: Scoping Review.

Receiving a diagnosis that leads to severe disability in childhood can cause a traumatic experience with long-lasting emotional stress for patients and family members. In recent decades, emerging digital technologies have transformed how patients or caregivers of persons with disabilities manage their health conditions. As a result, information (eg, on treatment and resources) has become widely available to patients and their families. Parents and other caregivers can use digital platforms such as websites or social media to derive social support, usually from other patients and caregivers who share their lived experiences, challenges, and successes on these platforms. However, gaps remain in our understanding of platforms that are most frequently used or preferred among parents and caregivers of children with disabilities. In particular, it is not clear what factors primarily drive or discourage engagement with these digital tools and what the main ethical considerations are in relation to these tools.
Oliver Gruebner, Afua van Haasteren, Anna Hug, Suzanne Elayan, Martin Sykora, Emiliano Albanese, John Naslund, Markus Wolf, Marta Fadda, Michael von Rhein

2635 related Products with: Digital Platform Uses for Help and Support Seeking of Parents With Children Affected by Disabilities: Scoping Review.

100ug96 Well500 ml2x96 well plate200ul 1 G 5 G10 mg 1 G1

Related Pathways

paperclip

#36472893   2022/12/06 To Up

Guideline on Treatment and Management of Craniosynostosis: Patient and Family Version.

The care and treatment of patients with craniosynostosis and the new developments were described for health care professionals involved in this in the guideline "Treatment and Management of Craniosynostosis", which was revised in 2020. A patient version was written based on the professional guideline to make the information accessible to patients and parents too. In this patient version, each chapter consists of several sections. Firstly, an introduction and background information is provided in each chapter. Various questions are then answered based on scientific literature. Finally, the recommendations indicate the importance of the literature for care in practice and how this care should be provided in practice. This patient version is an abbreviated and simplified representation of the professional guideline. The introduction, conclusions, and recommendations sections of each chapter were revised and, where necessary, rewritten. With some surgical techniques, links to animation videos (recognizable by underlined references) have been added in the text for clarification. An attempt was made to stay as close as possible to the original guideline in terms of content, questions, numbering, and classification. The patient version can therefore easily be read side by side with the professional guideline if more information is required about a specific subject. As this patient version is a summary and does not deal with all aspects in detail, no rights can be derived from its content and the professional guideline takes precedence at all times. Originally, this patient version has been written in response to the established Dutch guideline on craniosynostosis for health care professionals.2 This professional guideline has been specifically tailored to the Dutch health care setting and policy. There are however differences between health care systems and national health policies of other countries and the Netherlands. It is important to keep in mind that this may, at some points, result in the management of care in your country and/or hospital different from outlined here.
Mariët Faasse, Irene M J Mathijssen,

2001 related Products with: Guideline on Treatment and Management of Craniosynostosis: Patient and Family Version.

100ug1,000 tests200ug1 mg1000 TESTS/0.65ml1000 tests100 mg 100ul25 mg1000 10 mg

Related Pathways

paperclip

#36472875   2022/12/01 To Up

Association of Outpatient Behavioral Health Treatment With Medical and Pharmacy Costs in the First 27 Months Following a New Behavioral Health Diagnosis in the US.

Outpatient behavioral health treatment (OPBHT) is an effective treatment for behavioral health conditions (BHCs) that may also be associated with improved medical health outcomes, but evidence regarding the cost-effectiveness of OPBHT across a large population has not been established.
Johanna Bellon, Carol Quinlan, Beth Taylor, Douglas Nemecek, Eva Borden, Priya Needs

1977 related Products with: Association of Outpatient Behavioral Health Treatment With Medical and Pharmacy Costs in the First 27 Months Following a New Behavioral Health Diagnosis in the US.

1100ug Lyophilized100 ul100ug Lyophilized

Related Pathways

    No related Items
paperclip

#36472805   2022/12/06 To Up

Why Do So Many People with Type 2 Diabetes Who Take Insulin Have Lipohypertrophy? Fate or Educational Deficiencies?

Cutaneous lipohypertrophy (LH) is a thickened, "rubbery" lesion in the subcutaneous tissue following multiple injections performed at the same site, i.e., an incorrect injection technique. It is widespread, averaging 47% of insulin patients worldwide, and has severe direct and indirect consequences. Direct consequences consist mainly of poor metabolic control and frequent hypoglycemic events (HYPOs), and indirect ones of markedly increased healthcare costs related to hospital access due to acute events and long-term disease complications. This observation also holds for Italy, despite the National Health System organization expecting every patient with diabetes to undergo a series of visits by different care team members, each performing a specific treatment/education task. Indeed, the recent literature points to poor awareness of LH relevance and metabolic consequences among doctors from general and diabetic hospital wards, with educational deficiencies on correct injection practice in nurses too. The aim was to establish if, to what extent, and by whom they had received training on correct insulin injection techniques, and how many initially received notions had persisted over time.
Sandro Gentile, Giuseppina Guarino, Teresa Della Corte, Giampiero Marino, Ersilia Satta, Maria Pasquarella, Carmine Romano, Carmelo Alfarone, Laura Giordano, Fabrizio Loiacono, Maurizio Capece, Rossella Lamberti, Felice Strollo,

2284 related Products with: Why Do So Many People with Type 2 Diabetes Who Take Insulin Have Lipohypertrophy? Fate or Educational Deficiencies?

25 G50ug 100ul 100 G200ml250ul5 mg100ug200ul200ul 100ul

Related Pathways

paperclip

#36472760   2022/12/06 To Up

A Rising 2D Star: Novel MBenes with Excellent Performance in Energy Conversion and Storage.

As a flourishing member of the two-dimensional (2D) nanomaterial family, MXenes have shown great potential in various research areas. In recent years, the continued growth of interest in MXene derivatives, 2D transition metal borides (MBenes), has contributed to the emergence of this 2D material as a latecomer. Due to the excellent electrical conductivity, mechanical properties and electrical properties, thus MBenes attract more researchers' interest. Extensive experimental and theoretical studies have shown that they have exciting energy conversion and electrochemical storage potential. However, a comprehensive and systematic review of MBenes applications has not been available so far. For this reason, we present a comprehensive summary of recent advances in MBenes research. We started by summarizing the latest fabrication routes and excellent properties of MBenes. The focus will then turn to their exciting potential for energy storage and conversion. Finally, a brief summary of the challenges and opportunities for MBenes in future practical applications is presented.
Tianjie Xu, Yuhua Wang, Zuzhao Xiong, Yitong Wang, Yujin Zhou, Xifei Li

1684 related Products with: A Rising 2D Star: Novel MBenes with Excellent Performance in Energy Conversion and Storage.

1-8 Sample Kit100ug Lyophilized100 μg100 μg96 assays 100 μg2 mg100 μg

Related Pathways

paperclip

#36472749   2022/12/06 To Up

Comprehensive analysis of ERCC3 prognosis value and ceRNA network in AML.

Acute myeloid leukemia (AML) is a hematological malignancy with high molecular and clinical heterogeneity, and is the most common type of acute leukemia in adults. Due to limited treatment options, AML is prone to relapse and has a poor prognosis. Excision repair cross-complementing 3 (ERCC3) is an important member of nucleotide excision repair (NER) that is overexpressed in types of solid cancers and potentially regarded as a prognostic factor. However, its role in AML remains unclear. The purpose of this study was to explore ERCC3 expression and functions in AML.
Xiebing Bao, Yao Chen, Xiao Lou, Jiahui Du, Huijun Li, Nian Liu, Zaixiang Tang, Jingsheng Hua, Weiqiang Guo, Song-Bai Liu

1608 related Products with: Comprehensive analysis of ERCC3 prognosis value and ceRNA network in AML.

1-8 Sample Kit2 modules100 μg5 mg4 Arrays/Slide100 μg100ug Lyophilized100 μg

Related Pathways

paperclip

#36472675   2022/12/06 To Up

Family treatment for postpartum depression: acceptability, feasibility, and preliminary clinical outcomes.

The level of support from family members-and degree of family dysfunction-can shape the onset and course of maternal postpartum depression (PPD). In spite of this, family members are typically not included in treatments for PPD. Developing and disseminating intervention approaches that involve partners or other family members may lead to more effective treatment for perinatal women and potentially promote improved family functioning and wellbeing of multiple members of the family. To evaluate the feasibility and acceptability of a family-based treatment for PPD, we conducted an open pilot trial with 16 postpartum mother-father couples (N = 32 participants) and measured session attendance, patient satisfaction, and changes in key symptoms and functional outcomes. At the time of enrollment, mothers were 1-7 months postpartum, met criteria for major depressive disorder, and had moderate-severe symptoms of depression. Treatment involved 10-12 sessions attended by the mother along with an identified family member (all fathers) at each session. Findings provide strong support for the acceptability and feasibility of the intervention: session attendance rates were high, and participants evaluated the treatment as highly acceptable. Improvements in depression were observed among both mothers and fathers, and family functioning improved by the endpoint across several domains. Symptomatic and functional gains were sustained at follow-up. The current findings provide support for a larger randomized trial of family-based treatment for PPD.
Cynthia L Battle, Esteban V Cardemil, Rita Rossi, Michael W O'Hara, Ivan W Miller

1296 related Products with: Family treatment for postpartum depression: acceptability, feasibility, and preliminary clinical outcomes.

125 ml 100ul500 MG100ug Lyophilized1 mg

Related Pathways

paperclip

#36472643   2022/12/06 To Up

[Evaluation of clinical trials on medicinal products by ethics committees: changes due to the new EU Regulation 536/2014 (CTR) and necessary harmonization measures].

After Regulation (EU) No. 536/2014 (Clinical Trial Regulation, CTR) of the European Parliament and of the Council took effect on 31 January 2022, the application process for clinical trials fundamentally changed. This article describes the fundamental procedural changes and the resulting changes for Germany and, in particular, for the ethics committees. The harmonization efforts of the ethics committees at the EU level are discussed.According to the new EU regulation, only one ethics committee is involved in the approval of a clinical trial of medicinal products in Germany. The previous consultation procedure involving several locally competent ethics committees has been replaced. Instead, there is now closer cooperation between the ethics committees and the federal authorities through the preparation of a joint assessment report as well as with the other EU member states as part of the consolidation of the respective country-specific requirements. The regular mutual exchange between the ethics committees that had previously accompanied the consultation procedure helped to harmonize the decision criteria but also the discretionary decisions. Due to the discontinuation of this exchange, more detailed procedural recommendations are required but also other regular exchange possibilities in order to not only maintain but also to advance harmonizations already in place. The Working Group of Medical Ethics Committees (AKEK), as the representative of the individual ethics committees, also maintains an intensive exchange with federal authorities, applicants, other European ethics committees and European institutions.
Claudia Raffauf-Seufert, Guido Grass

1086 related Products with: [Evaluation of clinical trials on medicinal products by ethics committees: changes due to the new EU Regulation 536/2014 (CTR) and necessary harmonization measures].

100ug 100 G

Related Pathways

paperclip

#36472498   2022/12/06 To Up

Host-microbiome metabolism of a plant toxin in bees.

While foraging for nectar and pollen, bees are exposed to a myriad of xenobiotics, including plant metabolites, which may exert a wide range of effects on their health. Although the bee genome encodes enzymes that help in the metabolism of xenobiotics, it has lower detoxification gene diversity than the genomes of other insects. Therefore, bees may rely on other components that shape their physiology, such as the microbiota, to degrade potentially toxic molecules. In this study, we show that amygdalin, a cyanogenic glycoside found in honey bee-pollinated almond trees, can be metabolized by both bees and members of the gut microbiota. In microbiota-deprived bees, amygdalin is degraded into prunasin, leading to prunasin accumulation in the midgut and hindgut. In microbiota-colonized bees, on the other hand, amygdalin is degraded even further, and prunasin does not accumulate in the gut, suggesting that the microbiota contribute to the full degradation of amygdalin into hydrogen cyanide. experiments demonstrated that amygdalin degradation by bee gut bacteria is strain-specific and not characteristic of a particular genus or species. We found strains of , and that can degrade amygdalin. The degradation mechanism appears to vary since only some strains produce prunasin as an intermediate. Finally, we investigated the basis of degradation in wkB204, a strain that fully degrades amygdalin. We found overexpression and secretion of several carbohydrate-degrading enzymes, including one in glycoside hydrolase family 3 (GH3). We expressed this GH3 in and detected prunasin as a byproduct when cell lysates were cultured with amygdalin, supporting its contribution to amygdalin degradation. These findings demonstrate that both host and microbiota can act together to metabolize dietary plant metabolites.
Erick V S Motta, Alejandra Gage, Thomas E Smith, Kristin J Blake, Waldan K Kwong, Ian M Riddington, Nancy Moran

2072 related Products with: Host-microbiome metabolism of a plant toxin in bees.

0.1ml100 ul1 mg100 ug 50ul0.1ml96tests100 ug0.1ml (1.3mg/ml)200 ug200 ug

Related Pathways